New immune cell therapy tested for Tough-to-Treat skin cancer
NCT ID NCT05629546
Summary
This early-stage study is testing the safety of a new combination treatment for people with advanced melanoma that has continued to grow despite standard immunotherapy. The treatment involves infusing specially prepared 'memory-like' natural killer (NK) immune cells, either from the patient's own blood or from a donor, along with two immunotherapy drugs (nivolumab and relatlimab). The main goal is to see if this approach is safe and tolerable, while also checking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.